Clinical Trials
2
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
A Safety and Pharmacokinetics Study of RC220 Combined With Doxorubicin in Adult Participants With Solid Tumours.
- Conditions
- Solid TumoursAdvanced Solid Tumours
- Interventions
- First Posted Date
- 2025-02-07
- Last Posted Date
- 2025-09-08
- Lead Sponsor
- Race Oncology Ltd
- Target Recruit Count
- 53
- Registration Number
- NCT06815575
- Locations
- 🇦🇺
Gosford Hospital, Gosford, New South Wales, Australia
🇦🇺Cancer Care Foundation, Miranda, New South Wales, Australia
🇦🇺Wyong Hospital, Wyong, New South Wales, Australia
A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS
- Conditions
- Acute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaHigher Risk Myelodysplastic SyndromeChronic Myelomonocytic Leukemia
- Interventions
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Race Oncology Ltd
- Registration Number
- NCT05456269
- Locations
- 🇦🇺
Calvary Mater, Newcastle, New South Wales, Australia
News
Former J&J Executive Herwig Janssen Appointed Chairman of Tryptamine Therapeutics as Company Advances Psilocin-Based Clinical Programs
Tryptamine Therapeutics has appointed Herwig Janssen, a former Johnson & Johnson executive with 40+ years of pharmaceutical experience, as its new non-executive chairman effective May 12.
ASX Biotech Shares Surge on Cancer Trial Progress, Diagnostic Milestones
Race Oncology's stock jumped following the submission of a human ethics application for its RC220 Phase 1 solid tumour trial, with patient recruitment expected in Q1 2025.
Race Oncology's RC220 Phase 1 Trial Advances for Solid Tumors
Race Oncology has submitted ethics and regulatory documents for a Phase 1 trial of RC220 with doxorubicin, targeting advanced solid tumors.